Skip to main navigation

Overview
News & Events
- Press Releases
- Events and Presentations
Stock Information
- Stock Quote & Chart
- Analyst Coverage
Financials
Governance
IR Resources
- Email Alerts
- Contact IR

Events and Presentations

Events and Presentations

Presentations

June 7, 2022

Corporate Presentation June 2022

Asset Categories

Investor Presentation

Past Events

August 4, 2022

Phase II Drug Development for Alzheimer’s Disease: Athira Pharma

Scientific Presentation

August 3, 2022

ACT-AD: Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease – First Results of a Randomized, Placebo-Controlled, 26-Week, Phase 2 Proof-of-Concept Trial

Scientific Presentation

August 2, 2022

Fosgonimeton, a Novel, Small-Molecule Positive Modulator of the HGF/MET System, is Neuroprotective in Primary Neuron Culture

Scientific Presentation

July 31, 2022

Development of Stable, Orally Bioavailable, Small-Molecule Positive Modulators of HGF/MET Signaling for the Treatment of Cognitive Impairment

Scientific Presentation

June 22, 2022 at 8:30 AM EDT

Athira Pharma ACT-AD Phase 2 Topline Results Webcast

Investor Presentation

April 14, 2022 at 3:00 PM EDT

21st Annual Needham Virtual Healthcare Conference – April 11-14, 2022

Investor Presentation

March 28, 2022 at 2:30 PM EDT

Stifel 2022 Virtual CNS Days

Investor Presentation

March 24, 2022 at 4:30 PM EDT

Fourth Quarter and Full Year 2021 Financial Results and Business Update Conference Call

March 20, 2022

Study Design and Participant Characteristics of a Phase 2 Trial of Fosgonimeton, a Novel Treatment for Mild to Moderate Alzheimer’s Disease

Scientific Presentation

March 2, 2022

Oral Small Molecule Hepatocyte Growth Factor/MET Positive Modulator ATH-1020 Reduces Depression-like Behaviors and Normalizes Pathological EEG Mismatch Negativity in Preclinical Models

Scientific Presentation

Pagination

Current page 1
Page 2
Next page
Last page

SIGN UP FOR EMAIL ALERTS

CONTACT IR

Athira Pharma, Inc.
18706 North Creek Parkway
Suite 104
Bothell, WA 98011

Main line: (866) 725-0930
Local number: (425) 620-8501
info@athira.com

© Athira Pharma, Inc. All rights reserved.